These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 18765170)
61. Using Medicare administrative data to conduct postmarketing surveillance of follow-on biologics: issues and opportunities. DiMartino LD; Curtis LH; Williams RL; Abernethy DR; Schulman KA Food Drug Law J; 2008; 63(4):891-900. PubMed ID: 19601387 [No Abstract] [Full Text] [Related]
62. The evolving process of European combination product review, Part II. Donawa ME Med Device Technol; 2008; 19(7):26, 28-31. PubMed ID: 19133625 [TBL] [Abstract][Full Text] [Related]
63. [Prophylaxis in clinical medicine]. Markov AM Klin Med (Mosk); 1977 May; 55(5):3-7. PubMed ID: 875334 [No Abstract] [Full Text] [Related]
65. Heart aches for clean air. Harv Health Lett; 2005 Jul; 30(9):7. PubMed ID: 16163784 [No Abstract] [Full Text] [Related]
66. Use of saline contrast echo timing to distinguish intracardiac and extracardiac shunts: failure of the 3- to 5-beat rule. Freeman JA; Woods TD Echocardiography; 2008 Nov; 25(10):1127-30. PubMed ID: 18986396 [TBL] [Abstract][Full Text] [Related]
67. A global health strategy to capitalize on proven-effective interventions for heart, lung, and blood diseases. Engelgau MM; Peprah E; Sampson UK; Mensah GA Glob Heart; 2015 Mar; 10(1):87-91. PubMed ID: 25754575 [No Abstract] [Full Text] [Related]
68. How is a food product recalled? Cunningham E J Am Diet Assoc; 2009 Aug; 109(8):1488. PubMed ID: 19631055 [No Abstract] [Full Text] [Related]
69. Hydration protocols to reduce the incidence of contrast-induced nephropathy. Nikolsky E; Mehran R J Invasive Cardiol; 2008 Oct; 20(10):527-38. PubMed ID: 18829997 [No Abstract] [Full Text] [Related]
70. Significance of research in cardiopulmonary disease. MOERSCH HJ JAMA; 1961 Sep; 177():834-5. PubMed ID: 13771651 [No Abstract] [Full Text] [Related]
71. Myocardial contrast echo: current status and future directions. Nahar T Indian Heart J; 2007; 59(3):226-31. PubMed ID: 19124930 [TBL] [Abstract][Full Text] [Related]
73. [Never forget why you started, try the best to promote the healthy development of the prevention and rehabilitation for patients with cardiopulmonary diseases]. Hu DY Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Sep; 47(9):680-682. PubMed ID: 31550833 [TBL] [Abstract][Full Text] [Related]
74. Abstracts of the 5th Quebec International Symposium on Cardiopulmonary Prevention and Rehabilitation, Quebec City, Canada, June 13-15, 2007. Clin Invest Med; 2007; 30(3 Suppl):S26-48. PubMed ID: 17855832 [No Abstract] [Full Text] [Related]
75. Medical Device Manufacturing and Medical Device Reports (MDR). Arellano V Insight; 2009; 34(3):24-5. PubMed ID: 19708431 [No Abstract] [Full Text] [Related]
77. Importance of on-time RotaTeq vaccination and long-term active surveillance. Anderson EJ Pediatrics; 2008 Nov; 122(5):1153-4; author reply 1154. PubMed ID: 18977997 [No Abstract] [Full Text] [Related]
78. Postmarketing surveillance for oncology drugs. Viale PH; Moore S Clin J Oncol Nurs; 2008 Dec; 12(6):877-86. PubMed ID: 19064381 [TBL] [Abstract][Full Text] [Related]
79. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution? Faden LB; Milne CP Food Drug Law J; 2008; 63(3):683-700. PubMed ID: 19031668 [No Abstract] [Full Text] [Related]